Taxorest
Taxorest is a Khavinson short peptide bioregulator for the tracheal and bronchial epithelium. Proposed to support respiratory tract cell regeneration and gene expression in lung tissue aging. Used alongside Chonluten in pulmonary anti-aging protocols.
Community Rating
No ratings yet
Compound Profile
Taxorest
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Taxorest is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Proposed to support tracheal and bronchial epithelial cell gene expression and regeneration capacity
- Targeted at respiratory tract aging — the decline in mucociliary clearance and epithelial maintenance with age
- Complement to Chonluten (lung bioregulator) in respiratory system anti-aging protocols
- Taxorest is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Proposed to support tracheal and bronchial epithelial cell gene expression and regeneration capacity
- Targeted at respiratory tract aging — the decline in mucociliary clearance and epithelial maintenance with age
- Complement to Chonluten (lung bioregulator) in respiratory system anti-aging protocols
In Plain English
Simple summaryTaxorest is a synthetic tetrapeptide from the Khavinson bioregulator series targeted at thymus tissue -- specifically designed for use in respiratory/thymus immune interactions. The name is derived from the Russian word for the regulatory role it's proposed to play. Like other Khavinson bioregulators, it was extracted from target organ tissue, the active peptide fraction was characterized, and the shortest active sequence was synthesized. Taxorest is proposed to support thymic function specifically in the context of respiratory disease and immune reconstitution after pulmonary infections. It's part of the broader thymic bioregulator family that also includes Thymalin and Thymagen.
- Proposed to support tracheal and bronchial epithelial cell gene expression and regeneration capacity
- Targeted at respiratory tract aging — the decline in mucociliary clearance and epithelial maintenance with age
- Complement to Chonluten (lung bioregulator) in respiratory system anti-aging protocols
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Taxorest?
Tap any underlined term for an instant definition.
Taxorest is a peptide bioregulator from Professor Khavinson's research program, derived from tracheal/tracheobronchial tissue, targeting the upper and central airways. It is differentiated from Chonluten (which targets pulmonary alveolar tissue) by its focus on the tracheal and bronchial epithelium — the ciliated airway epithelium responsible for mucociliary clearance.
Age-related changes in the respiratory epithelium include: reduced cilia beat frequency, impaired mucociliary transport (critical for clearing inhaled particles and pathogens), reduced secretory IgA production, decreased airway stem cell proliferation capacity, and impaired repair after injury. These changes contribute to increased susceptibility to respiratory infections and slower recovery in elderly individuals.
Taxorest is proposed to target respiratory epithelial cell gene expression, potentially supporting ciliated cell maintenance, mucus production regulation, and epithelial barrier function. In the Khavinson bioregulator system, it is often paired with Chonluten for comprehensive respiratory tract support.
As with other Khavinson bioregulators, the primary evidence base consists of publications from the St. Petersburg Institute of Bioregulation and Gerontology in Russian-language journals and translated journals (Advances in Gerontology, Bulletin of Experimental Biology and Medicine). Independent replication in Western clinical settings is limited.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Taxorest. See all Immune System peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Oral capsule. Part of the Khavinson Institute respiratory system bioregulator approach.
What the research doesn't show
Taxorest follows the standard Khavinson bioregulator evidence pattern. The lung-thymus immune connection is biologically real, but whether this specific tetrapeptide sequence specifically addresses it is not demonstrated by independent research. All claims should be interpreted with the same level of skepticism appropriate for the Khavinson bioregulator class generally.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Taxorest, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Taxorest has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: proposed to support tracheal and bronchial epithelial cell gene expression and regeneration capacity.
The most commonly reported side effect in research subjects is minimal adverse effects in the khavinson program. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Thymalin, Thymagen, and Vilon are the other thymic bioregulators in the Khavinson series. Thymosin alpha-1 has international recognition and Phase 3 trials in viral hepatitis and lung infections. LL-37 provides genuine innate immune support in respiratory epithelia with well-characterized mechanisms. Taxorest has a much narrower and less independent evidence base.
Compare Taxorest side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.